Redx Pharma logo

REDX - Redx Pharma Share Price

7.5p 0.0  0.0%

Last Trade - 17/10/19

Sector
Healthcare
Size
Micro Cap
Market Cap £9.49m
Enterprise Value £6.17m
Revenue £n/a
Position in Universe 1555th / 1855
Bullish
Bearish
Unlock REDX Revenue
Momentum
Relative Strength (%)
1m
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Margin of Safety
Qualifying GuruScreens
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

REDX Revenue Unlock REDX Revenue

Net Income

REDX Net Income Unlock REDX Revenue

Normalised EPS

REDX Normalised EPS Unlock REDX Revenue

PE Ratio Range

REDX PE Ratio Range Unlock REDX Revenue

Dividend Yield Range

REDX Dividend Yield Range Unlock REDX Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2019
31st Dec 2020
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
REDX EPS Forecasts Unlock REDX Revenue
Profile Summary

Redx Pharma Plc, is engaged in drug discovery, pre-clinical development and licensing. It is engaged in drug discovery across cancer, infection and autoimmune diseases. It has over three programs like Porcupine RXC004 is a combination with PD-1 / PD-L1 in solid tumor (colorectal cancer), GI-targeted ROCK is focused on Crohn’s disease, Porcupine (REDX06109) is focused on Idiopathic pulmonary fibrosis (IPF), ROCK2 selective is focused on Non-alcoholic Steatohepatitis (NASH) and research in Validated targets (SHP2, AZ collaboration and undisclosed targets) focused in Cancer & Fibrosis which has reached candidate nomination stage. Its anti-infective candidate compound is an antibiotic that the Company has developed to treat a range of Gram-positive bacterial infections, including resistant strains, such as Methicillin-Resistant Staphylococcus Aureus (MRSA). Its product candidate, RDX004, is a class of antibiotic acting through the type II bacterial topoisomerases.

Directors
Last Annual September 30th, 2018
Last Interim March 31st, 2019
Incorporated September 7, 2010
Public Since March 27, 2015
No. of Shareholders: n/a
No. of Employees: 52
Sector Healthcare
Industry Biotechnology & Medical Research
Index FTSE Aim All Share ,
Exchange London Stock Exchange (Full)
Shares in Issue 126,477,914
Free Float (0.0%)
Eligible for
ISAs
SIPPs
REDX Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for REDX
Upcoming Events for REDX
Thursday 23rd January, 2020 Estimate
Redx Pharma PLC Annual Shareholders Meeting
Similar to REDX
© Stockopedia 2019, Thomson Reuters, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.